ESMO 2022: Patient-Reported Outcomes Good With Trastuzumab-Deruxtecan in HER2-Low Metastatic Breast Cancer
Health-related quality of life maintained longer with T-DXd treatment versus treatment of physician’s choice
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.